Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 10/20 | 0.44 |
| ▸ | JAK2 | O60674 | 9/20 | 0.44 |
| ▸ | JAK1 | P23458 | 9/20 | 0.44 |
| ▸ | JAK3 | P52333 | 9/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5458116 | 0.82 | JAK2 (0.41) | TYK2JAK2JAK1JAK3 | |
| SCHEMBL6372922 | 0.75 | JAK2 (0.60) | TYK2JAK2JAK1JAK3MAP4K4 | |
| SCHEMBL5463483 | 0.75 | JAK2 (0.65) | TYK2JAK2JAK1JAK3MAP4K4 | |
| SCHEMBL13606479 | 0.75 | FYN (0.44) | — | |
| SCHEMBL5241264 | 0.73 | HTT (0.45) | TYK2JAK2JAK1JAK3NPC1 | |
| SCHEMBL2779227 | 0.71 | NPC1 (0.46) | NPC1RAB9ACYP11B1CYP11B2MAP4K4 | |
| SCHEMBL15161349 | 0.69 | MAP4K4 (0.62) | CYP11B1CYP11B2MAP4K4 | |
| SCHEMBL4506115 | 0.68 | JAK2 (0.43) | TYK2JAK2JAK1JAK3NPC1 | |
| SCHEMBL3592428 | 0.67 | PTGS1 (0.41) | TYK2JAK2CYP11B1CYP11B2 | |
| SCHEMBL13606550 | 0.67 | JAK2 (0.58) | TYK2JAK2JAK1JAK3MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244146-A1 | Thienopyridines as IKK inhibitors | TALAMAS FRANCISCO X | 2007-10-18 | — | — | US | disclosed |
| US-20070244146-A1 | Thienopyridines as IKK inhibitors | TALAMAS FRANCISCO X | 2007-10-18 | — | — | US | disclosed |
| US-20070244146-A1 | Thienopyridines as IKK inhibitors | TALAMAS FRANCISCO X | 2007-10-18 | — | — | US | disclosed |
| US-20050272762-A1 | Thienopyridines as IKK inhibitors | ROCHE PALO ALTO LLC | 2005-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272762-A1 | Thienopyridines as IKK inhibitors | NFKBIA, IKBKE, IKBKB | TYK2 207/4885JAK2 85/4885JAK1 48/4885 |
| US-20070244146-A1 | Thienopyridines as IKK inhibitors | NFKBIA, IKBKE, IKBKB | TYK2 207/4885JAK2 85/4885JAK1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.